Press coverage about Edwards Lifesciences Corp (NYSE:EW) has been trending positive on Thursday, AlphaOne Sentiment Analysis reports. The research group, a service of Accern, rates the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. AlphaOne ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Edwards Lifesciences Corp earned a coverage optimism score of 0.39 on AlphaOne’s scale. AlphaOne also gave media stories about the medical research company an impact score of 75 out of 100, meaning that recent media coverage is likely to have an effect on the stock’s share price in the next several days.
Here are some of the news articles that may have impacted AlphaOne Sentiment’s analysis:
- QUALCOMM (NASDAQ:QCOM) Helping Ease Concerns Surrounding The Company’s Dispute With Apple Inc. (emarketsdaily.com)
- Trust Department MB Financial Bank N A Sells 2,056 Shares of Edwards Lifesciences Corp (EW) (automotive.einnews.com)
- Edward Lifesciences (EW) Q1 Earnings: A Surprise in Store? (finance.yahoo.com)
- Edwards Lifesciences (EW) Announces FDA Clearance for Advanced Hemodynamic Monitoring Platform (streetinsider.com)
- Farmers & Merchants Investments Inc. Has $2.759 Million Position in Edwards Lifesciences Corp (footballhebdo.com)
Several equities research analysts recently issued reports on EW shares. Guggenheim upgraded shares of Edwards Lifesciences Corp from a “neutral” rating to a “buy” rating and set a $120.00 price objective for the company in a research report on Tuesday, January 3rd. Vetr cut shares of Edwards Lifesciences Corp from a “strong-buy” rating to a “buy” rating and set a $106.00 price objective for the company. in a research report on Tuesday, January 3rd. BTIG Research cut shares of Edwards Lifesciences Corp from a “buy” rating to a “neutral” rating in a research report on Thursday, February 2nd. They noted that the move was a valuation call. Leerink Swann cut shares of Edwards Lifesciences Corp from an “outperform” rating to a “market perform” rating in a research report on Thursday, February 2nd. Finally, Northland Securities restated a “positive” rating and set a $105.00 price objective on shares of Edwards Lifesciences Corp in a research report on Thursday, February 2nd. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $118.34.
Shares of Edwards Lifesciences Corp (NYSE:EW) traded up 1.88% on Thursday, reaching $98.51. 1,964,171 shares of the company were exchanged. The company has a 50-day moving average price of $93.81 and a 200 day moving average price of $95.49. Edwards Lifesciences Corp has a 1-year low of $81.12 and a 1-year high of $121.75. The stock has a market capitalization of $20.93 billion, a PE ratio of 37.74 and a beta of 0.53.
Edwards Lifesciences Corp (NYSE:EW) last released its earnings results on Wednesday, February 1st. The medical research company reported $0.75 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.72 by $0.03. The company earned $767.70 million during the quarter, compared to analysts’ expectations of $760.85 million. Edwards Lifesciences Corp had a return on equity of 25.00% and a net margin of 19.22%. The business’s revenue was up 14.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.64 EPS. On average, analysts forecast that Edwards Lifesciences Corp will post $3.41 EPS for the current fiscal year.
In other news, Director Kieran Gallahue acquired 3,000 shares of Edwards Lifesciences Corp stock in a transaction that occurred on Friday, February 3rd. The shares were purchased at an average cost of $90.10 per share, for a total transaction of $270,300.00. Following the completion of the purchase, the director now directly owns 2,524 shares of the company’s stock, valued at approximately $227,412.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Patrick B. Verguet sold 24,000 shares of the firm’s stock in a transaction on Thursday, March 30th. The stock was sold at an average price of $93.90, for a total value of $2,253,600.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 100,540 shares of company stock valued at $9,173,288. Company insiders own 2.37% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Positive Press Coverage Likely to Impact Edwards Lifesciences Corp (EW) Share Price” was first posted by WKRB News and is the property of of WKRB News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at http://www.wkrb13.com/markets/2065615/positive-press-coverage-likely-to-impact-edwards-lifesciences-corp-ew-share-price.html.
Edwards Lifesciences Corp Company Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
This story was originally published by WKRB News (http://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://www.wkrb13.com/markets/2065615/positive-press-coverage-likely-to-impact-edwards-lifesciences-corp-ew-share-price.html
Receive News & Ratings for Edwards Lifesciences Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corp and related companies with MarketBeat.com's FREE daily email newsletter.